Sarah Faubel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Faubel has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Kayo Okamura
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
5 shared publications Kayo Okamura
Division of Renal Diseases and Hypertension, Department of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
4 shared publicationsZhibin He
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
4 shared publicationsBenjamin R. Griffin
Department of Medicine, Division of Nephrology, University of Iowa Carver College of Medicine, Iowa City, USA
3 shared publicationsChris Altmann
3 shared publications- Isadore Budnick
Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
3 shared publications
Latest Publications
- 1 June 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330  (6) , F683-F701
Plasma metabolomics analysis in murine prerenal azotemia reveals changes in energy substrates, amino acid metabolism, and uremic toxins
We completed the first untargeted plasma metabolomics analysis in a murine model of prerenal azotemia (PRA) and demonstrate that PRA has systemic consequences with numerous significantly altered metabolites and pathways. By comparing the metabolite signature to that of acute tubular injury (ATI), novel insights into the potential adverse consequences of PRA and potential methods to distinguish PRA from ATI were identified.
- 1 June 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330  (6) , F683-F701
Plasma metabolomics analysis in murine prerenal azotemia reveals changes in energy substrates, amino acid metabolism, and uremic toxins
We completed the first untargeted plasma metabolomics analysis in a murine model of prerenal azotemia (PRA) and demonstrate that PRA has systemic consequences with numerous significantly altered metabolites and pathways. By comparing the metabolite signature to that of acute tubular injury (ATI), novel insights into the potential adverse consequences of PRA and potential methods to distinguish PRA from ATI were identified.
- Open Access
- 4 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7  (7) , 1522-1534
Thyroid Function with Continuous KRT
Background: AKI and ESKD requiring continuous kidney replacement therapy (CKRT) are associated with a high mortality rate. Solutes up to 40 kilodaltons (kDa) in size are amenable to CKRT clearance which includes thyroid stimulating hormone (TSH) (28 kDa), free thyroxine (fT4) (0.78 kDa), and free triiodothyronine (fT3) (0.68 kDa). The effect of CKRT on TSH and thyroid hormone clearance, thyroid function, and the hypothalamic-pituitary-thyroid (HPT) axis is unknown. Methods: This prospective, single-center observational study enrolled 50 ICU patients requiring CKRT and 50 control ICU patients. Serum TSH, fT4, fT3, and reverse T3 (rT3) were measured prior to and on days 1, 3, 8, and 14 after CKRT initiation and at the same time points relative to enrollment in control patients; effluent TSH, fT4, and fT3 were measured on days 1, 3, 8, and 14. Thyroid function status was adjudicated on days 1, 3, 8, and 14. Statistical analyses included employment of linear mixed modelling and time-dependent adjustments, and ANOVA with FDR correction. Results: Prior to and during CKRT, CKRT patients had lower fT4 and fT3 levels compared to controls, with a higher proportion of values below the normal reference range. TSH and fT4 were detected in the CKRT effluent, indicating clearance by CKRT. Severe and persistent non-thyroidal illness syndrome (NTIS) was seen in the CKRT cohort. No patient achieved euthyroid status while receiving CKRT. Conclusions: This is the first study to assess thyroid function and clearance of TSH and thyroid hormones during CKRT. We demonstrate that severe NTIS – characterized by low levels of fT4 and fT3 – occurs in the majority of CKRT patients. Furthermore, NTIS is persistent in patients receiving CKRT, which may be influenced by CKRT-mediated TSH and fT4 clearance. These novel complications may contribute to the high mortality rate observed in patients with either AKI or ESKD who receive CKRT.
- 4 May 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7  (7) , 1522-1534
Open AccessThyroid Function with Continuous KRT
Background: AKI and ESKD requiring continuous kidney replacement therapy (CKRT) are associated with a high mortality rate. Solutes up to 40 kilodaltons (kDa) in size are amenable to CKRT clearance which includes thyroid stimulating hormone (TSH) (28 kDa), free thyroxine (fT4) (0.78 kDa), and free triiodothyronine (fT3) (0.68 kDa). The effect of CKRT on TSH and thyroid hormone clearance, thyroid function, and the hypothalamic-pituitary-thyroid (HPT) axis is unknown. Methods: This prospective, single-center observational study enrolled 50 ICU patients requiring CKRT and 50 control ICU patients. Serum TSH, fT4, fT3, and reverse T3 (rT3) were measured prior to and on days 1, 3, 8, and 14 after CKRT initiation and at the same time points relative to enrollment in control patients; effluent TSH, fT4, and fT3 were measured on days 1, 3, 8, and 14. Thyroid function status was adjudicated on days 1, 3, 8, and 14. Statistical analyses included employment of linear mixed modelling and time-dependent adjustments, and ANOVA with FDR correction. Results: Prior to and during CKRT, CKRT patients had lower fT4 and fT3 levels compared to controls, with a higher proportion of values below the normal reference range. TSH and fT4 were detected in the CKRT effluent, indicating clearance by CKRT. Severe and persistent non-thyroidal illness syndrome (NTIS) was seen in the CKRT cohort. No patient achieved euthyroid status while receiving CKRT. Conclusions: This is the first study to assess thyroid function and clearance of TSH and thyroid hormones during CKRT. We demonstrate that severe NTIS – characterized by low levels of fT4 and fT3 – occurs in the majority of CKRT patients. Furthermore, NTIS is persistent in patients receiving CKRT, which may be influenced by CKRT-mediated TSH and fT4 clearance. These novel complications may contribute to the high mortality rate observed in patients with either AKI or ESKD who receive CKRT.
- Open Access
- 13 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16  (1)
Metabolomic assessment reveals depletion of amino acids and energy metabolites in skeletal muscle after ischemic acute kidney injury in mice
Acute kidney injury (AKI) is a systemic catabolic condition that affects multiple organs. Clinically, AKI has been associated with muscle wasting, weakness, and delayed functional recovery. The underlying biochemical mechanisms driving these changes are not well understood. Ischemic AKI was induced in 8-10-week-old male C57BL/6 mice. Untargeted metabolomics on gastrocnemius samples were performed via ultra-high performance liquid chromatography-mass spectrometry at 24 h and 72 h after AKI. Of the 175 annotated analytes identified, 72 were significantly affected at 24 h with the majority of these metabolites being depleted in AKI compared to controls. Key depleted metabolites included multiple amino acids, glutathione and its precursors, and other energy-related substrates. Integration with our previously published metabolomics data in the kidney, liver, heart, and plasma highlights shared metabolic pathways across these organs, particularly reflected in arginine metabolism and the urea cycle, alanine/aspartate/glutamate metabolism, and glutathione/redox balance. This is the first study to characterize the metabolic profile of skeletal muscle after ischemic AKI in a murine model. Our data deepen the understanding of AKI as a systemic metabolic disease, underscoring the need to further understand the effects of AKI on skeletal muscle and opening potential avenues for therapeutic strategies to improve outcomes after AKI.
- 13 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16  (1)
Open AccessMetabolomic assessment reveals depletion of amino acids and energy metabolites in skeletal muscle after ischemic acute kidney injury in mice
Acute kidney injury (AKI) is a systemic catabolic condition that affects multiple organs. Clinically, AKI has been associated with muscle wasting, weakness, and delayed functional recovery. The underlying biochemical mechanisms driving these changes are not well understood. Ischemic AKI was induced in 8-10-week-old male C57BL/6 mice. Untargeted metabolomics on gastrocnemius samples were performed via ultra-high performance liquid chromatography-mass spectrometry at 24 h and 72 h after AKI. Of the 175 annotated analytes identified, 72 were significantly affected at 24 h with the majority of these metabolites being depleted in AKI compared to controls. Key depleted metabolites included multiple amino acids, glutathione and its precursors, and other energy-related substrates. Integration with our previously published metabolomics data in the kidney, liver, heart, and plasma highlights shared metabolic pathways across these organs, particularly reflected in arginine metabolism and the urea cycle, alanine/aspartate/glutamate metabolism, and glutathione/redox balance. This is the first study to characterize the metabolic profile of skeletal muscle after ischemic AKI in a murine model. Our data deepen the understanding of AKI as a systemic metabolic disease, underscoring the need to further understand the effects of AKI on skeletal muscle and opening potential avenues for therapeutic strategies to improve outcomes after AKI.
- 5 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (3) , 361-363
What is Outpatient AKI? Insights from the SPRINT AKI Cohort
- 5 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (3) , 361-363
What is Outpatient AKI? Insights from the SPRINT AKI Cohort
- 27 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36  (12) , 2317-2319
Acute Cardiac Injury Mediates a Distinct Form of CKD
- 27 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36  (12) , 2317-2319
Acute Cardiac Injury Mediates a Distinct Form of CKD
- Open Access
- 30 April 2025
- Published by Springer Nature in Critical Care
- Vol. 29  (1) , 1-13
Procalcitonin levels in septic and nonseptic subjects with AKI and ESKD prior to and during continuous kidney replacement therapy (CKRT)
Procalcitonin is a 14.5 kDa protein used clinically as a marker of sepsis and therapeutic response to antibiotic therapy. However, its utility in critically ill patients with either acute kidney injury (AKI) or end-stage kidney disease (ESKD) who require continuous kidney replacement therapy (CKRT) is unknown. The aim of this study was to determine if plasma levels of procalcitonin could reliably distinguish septic from nonseptic status in patients with AKI or ESKD prior to or during CKRT. Procalcitonin concentrations were measured in plasma of 41 critically ill septic or non-septic subjects with AKI or ESKD prior to CKRT (pre-CKRT) and on days 1, 2, and 3 of CKRT in this retrospective cohort study (n = 111 total plasma measurements). Continuous venovenous hemodialysis was the modality of CKRT in these patients. Sepsis status was stringently defined based on culture results. Effluent procalcitonin levels were ascertained on days 1, 2, and 3 of CKRT to assess the clearance of procalcitonin and effects on plasma levels. 92% (66/72) of the plasma procalcitonin measurements among nonseptic patients with either AKI or ESKD were ≥ 0.5 ng/mL (the diagnostic threshold beyond which bacterial infection is very likely). Prior to CKRT initiation, procalcitonin levels were (median (IQR), ng/mL) 5.6 (1.5–18.9) in nonseptic AKI and 58.1 (6.9–195.5) in septic AKI (P = 0.03) and were 3.3 (1.2–8.3) in nonseptic ESKD and 3.7 (1.4–209.8) in septic ESKD (P = 0.79). However, despite being significantly elevated in septic patients with AKI, substantial overlap among procalcitonin levels was present and ROC curve analysis found no cut point that could reliably separate septic from nonseptic patients. Effluent procalcitonin levels were consistently ~ 20% of plasma levels throughout the course of CKRT (i.e., sieving coefficient was 0.2) suggesting that clearance occurs during therapy. However, plasma procalcitonin levels did not significantly decline during CKRT in either AKI or ESKD. Procalcitonin levels are markedly elevated in nonseptic critically ill patients with either AKI or ESKD and do not effectively distinguish sepsis from nonseptic status prior to or during CKRT. We conclude that procalcitonin testing should be avoided in critically ill patients with kidney failure since results are nonspecific in this population.
- 30 April 2025
- Published by Springer Nature in Critical Care
- Vol. 29  (1) , 1-13
Open AccessProcalcitonin levels in septic and nonseptic subjects with AKI and ESKD prior to and during continuous kidney replacement therapy (CKRT)
Procalcitonin is a 14.5 kDa protein used clinically as a marker of sepsis and therapeutic response to antibiotic therapy. However, its utility in critically ill patients with either acute kidney injury (AKI) or end-stage kidney disease (ESKD) who require continuous kidney replacement therapy (CKRT) is unknown. The aim of this study was to determine if plasma levels of procalcitonin could reliably distinguish septic from nonseptic status in patients with AKI or ESKD prior to or during CKRT. Procalcitonin concentrations were measured in plasma of 41 critically ill septic or non-septic subjects with AKI or ESKD prior to CKRT (pre-CKRT) and on days 1, 2, and 3 of CKRT in this retrospective cohort study (n = 111 total plasma measurements). Continuous venovenous hemodialysis was the modality of CKRT in these patients. Sepsis status was stringently defined based on culture results. Effluent procalcitonin levels were ascertained on days 1, 2, and 3 of CKRT to assess the clearance of procalcitonin and effects on plasma levels. 92% (66/72) of the plasma procalcitonin measurements among nonseptic patients with either AKI or ESKD were ≥ 0.5 ng/mL (the diagnostic threshold beyond which bacterial infection is very likely). Prior to CKRT initiation, procalcitonin levels were (median (IQR), ng/mL) 5.6 (1.5–18.9) in nonseptic AKI and 58.1 (6.9–195.5) in septic AKI (P = 0.03) and were 3.3 (1.2–8.3) in nonseptic ESKD and 3.7 (1.4–209.8) in septic ESKD (P = 0.79). However, despite being significantly elevated in septic patients with AKI, substantial overlap among procalcitonin levels was present and ROC curve analysis found no cut point that could reliably separate septic from nonseptic patients. Effluent procalcitonin levels were consistently ~ 20% of plasma levels throughout the course of CKRT (i.e., sieving coefficient was 0.2) suggesting that clearance occurs during therapy. However, plasma procalcitonin levels did not significantly decline during CKRT in either AKI or ESKD. Procalcitonin levels are markedly elevated in nonseptic critically ill patients with either AKI or ESKD and do not effectively distinguish sepsis from nonseptic status prior to or during CKRT. We conclude that procalcitonin testing should be avoided in critically ill patients with kidney failure since results are nonspecific in this population.
- 21 August 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (11) , 1395-1404
Cystatin C and Kidney Function Recovery in Patients Requiring Continuous KRT for Acute Kidney Injury
Key Points: Plasma cystatin C is decreased in participants with AKI requiring continuous KRT (CKRT) with early kidney function recovery. Despite being cleared by CKRT, plasma cystatin C in the first 3 days of CKRT may be a useful clinical tool to help predict the prognosis of AKI requiring CKRT. Background: Plasma cystatin C is a reliable marker to estimate kidney function; however, it is unknown whether this remains true in patients receiving continuous KRT (CKRT). In this study, we tested the hypothesis that lower concentrations of plasma cystatin C during the first 3 days of CKRT would predict kidney function recovery. Methods: We performed a retrospective observational study of 72 patients from a 126-patient, single-center CKRT study. We studied two a priori defined cohorts of patients without advanced CKD who had AKI requiring CKRT: (1) with early kidney function recovery defined as liberation from KRT within 7 days of CKRT initiation versus (2) with delayed kidney function recovery defined as receipt of KRT for >21 days or death while on KRT. Subsequent analysis included patients with advanced CKD and intermediate kidney function recovery (liberation between 8 and 21 days). Cystatin C was then measured on stored plasma, urine, and dialysis effluent collected before CKRT initiation and on days 1, 2, and 3 of CKRT. Results: Plasma cystatin C was significantly lower in patients with early kidney function recovery in comparison with patients with delayed kidney function recovery on days 1 (1.79 versus 2.39 mg/L), 2 (1.91 versus 2.38 mg/L), and 3 (2.04 versus 2.67 mg/L) of CKRT. Sieving coefficient and CKRT clearance of cystatin C were similar for patients with early and delayed kidney function recovery. The lowest plasma cystatin C concentration on days 1–3 of CKRT predicted early kidney function recovery with an area under the receiver operating curve of 0.77 (P=0.002), positive likelihood ratio of 5.60 for plasma cystatin C <1.30 mg/L, and negative likelihood ratio of 0.17 for plasma cystatin C ≥1.88 mg/L. Conclusions: Lower plasma cystatin C concentrations during the first 3 days of CKRT are associated with early kidney function recovery.
- 21 August 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (11) , 1395-1404
Cystatin C and Kidney Function Recovery in Patients Requiring Continuous KRT for Acute Kidney Injury
Key Points: Plasma cystatin C is decreased in participants with AKI requiring continuous KRT (CKRT) with early kidney function recovery. Despite being cleared by CKRT, plasma cystatin C in the first 3 days of CKRT may be a useful clinical tool to help predict the prognosis of AKI requiring CKRT. Background: Plasma cystatin C is a reliable marker to estimate kidney function; however, it is unknown whether this remains true in patients receiving continuous KRT (CKRT). In this study, we tested the hypothesis that lower concentrations of plasma cystatin C during the first 3 days of CKRT would predict kidney function recovery. Methods: We performed a retrospective observational study of 72 patients from a 126-patient, single-center CKRT study. We studied two a priori defined cohorts of patients without advanced CKD who had AKI requiring CKRT: (1) with early kidney function recovery defined as liberation from KRT within 7 days of CKRT initiation versus (2) with delayed kidney function recovery defined as receipt of KRT for >21 days or death while on KRT. Subsequent analysis included patients with advanced CKD and intermediate kidney function recovery (liberation between 8 and 21 days). Cystatin C was then measured on stored plasma, urine, and dialysis effluent collected before CKRT initiation and on days 1, 2, and 3 of CKRT. Results: Plasma cystatin C was significantly lower in patients with early kidney function recovery in comparison with patients with delayed kidney function recovery on days 1 (1.79 versus 2.39 mg/L), 2 (1.91 versus 2.38 mg/L), and 3 (2.04 versus 2.67 mg/L) of CKRT. Sieving coefficient and CKRT clearance of cystatin C were similar for patients with early and delayed kidney function recovery. The lowest plasma cystatin C concentration on days 1–3 of CKRT predicted early kidney function recovery with an area under the receiver operating curve of 0.77 (P=0.002), positive likelihood ratio of 5.60 for plasma cystatin C <1.30 mg/L, and negative likelihood ratio of 0.17 for plasma cystatin C ≥1.88 mg/L. Conclusions: Lower plasma cystatin C concentrations during the first 3 days of CKRT are associated with early kidney function recovery.
- Open Access
- 15 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14  (1) , 1-18
Disruption in glutathione metabolism and altered energy production in the liver and kidney after ischemic acute kidney injury in mice
Acute kidney injury (AKI) is a systemic disease that affects energy metabolism in various remote organs in murine models of ischemic AKI. However, AKI-mediated effects in the liver have not been comprehensively assessed. After inducing ischemic AKI in 8–10-week-old, male C57BL/6 mice, mass spectrometry metabolomics revealed that the liver had the most distinct phenotype 24 h after AKI versus 4 h and 7 days. Follow up studies with in vivo [13C6]-glucose tracing on liver and kidney 24 h after AKI revealed 4 major findings: (1) increased flux through glycolysis and the tricarboxylic (TCA) cycle in both kidney and liver; (2) depleted hepatic glutathione levels and its intermediates despite unchanged level of reactive oxygen species, suggesting glutathione consumption exceeds production due to systemic oxidative stress after AKI; (3) hepatic ATP depletion despite unchanged rate of mitochondrial respiration, suggesting increased ATP consumption relative to production; (4) increased hepatic and renal urea cycle intermediates suggesting hypercatabolism and upregulation of the urea cycle independent of impaired renal clearance of nitrogenous waste. Taken together, this is the first study to describe the hepatic metabolome after ischemic AKI in a murine model and demonstrates that there is significant liver-kidney crosstalk after AKI.
- 15 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14  (1) , 1-18
Open AccessDisruption in glutathione metabolism and altered energy production in the liver and kidney after ischemic acute kidney injury in mice
Acute kidney injury (AKI) is a systemic disease that affects energy metabolism in various remote organs in murine models of ischemic AKI. However, AKI-mediated effects in the liver have not been comprehensively assessed. After inducing ischemic AKI in 8–10-week-old, male C57BL/6 mice, mass spectrometry metabolomics revealed that the liver had the most distinct phenotype 24 h after AKI versus 4 h and 7 days. Follow up studies with in vivo [13C6]-glucose tracing on liver and kidney 24 h after AKI revealed 4 major findings: (1) increased flux through glycolysis and the tricarboxylic (TCA) cycle in both kidney and liver; (2) depleted hepatic glutathione levels and its intermediates despite unchanged level of reactive oxygen species, suggesting glutathione consumption exceeds production due to systemic oxidative stress after AKI; (3) hepatic ATP depletion despite unchanged rate of mitochondrial respiration, suggesting increased ATP consumption relative to production; (4) increased hepatic and renal urea cycle intermediates suggesting hypercatabolism and upregulation of the urea cycle independent of impaired renal clearance of nitrogenous waste. Taken together, this is the first study to describe the hepatic metabolome after ischemic AKI in a murine model and demonstrates that there is significant liver-kidney crosstalk after AKI.
- 3 November 2023
- Published by S. Karger AG in Blood Purification
- Vol. 53  (1) , 23-29
Hepcidin Removal during Continuous Renal Replacement Therapy
Introduction: Patients with acute kidney injury (AKI) or end stage kidney disease (ESKD) may require continuous renal replacement therapy (CRRT) as a supportive intervention. While CRRT is effective at achieving solute control and fluid balance, the indiscriminate nature of this procedure raises the possibility that beneficial substances may similarly be removed. Hepcidin, an antimicrobial peptide with pivotal roles in iron homeostasis and pathogen clearance, has biochemical properties amenable to direct removal via CRRT. We hypothesized that serum hepcidin levels would significantly decrease after initiation of CRRT. Methods: In this prospective, observational trial, we enrolled 13 patients who required CRRT: 11 due to stage 3 AKI, and 2 due to critical illness in the setting of ESKD. Plasma was collected at the time of enrollment, and then plasma and effluent were collected at 10:00 a.m. on the following 3 days. Plasma samples were also collected from healthy controls, and we compared hepcidin concentrations in those with renal disease compared to normal controls, evaluated trends in hepcidin levels over time, and calculated the hepcidin sieving coefficient. Results: Plasma hepcidin levels were significantly higher in patients initiating CRRT than in normal controls (158 ± 60 vs. 17 ± 3 ng/mL respectively, p < 0.001). Hepcidin levels were highest prior to CRRT initiation (158 ± 60 ng/mL), and were significantly lower on day 1 (102 ± 24 ng/mL, p < 0.001) and day 2 (56 ± 14 ng/mL, p < 0.001) before leveling out on day 3 (51 ± 11 ng/mL). The median sieving coefficient was consistent at 0.82–0.83 for each of 3 days. Conclusions: CRRT initiation is associated with significant decreases in plasma hepcidin levels over the first 2 days of treatment regardless of indication for CRRT, or presence of underlying ESKD. Since reduced hepcidin levels are associated with increased mortality and our data implicate CRRT in hepcidin removal, larger clinical studies evaluating relevant clinical outcomes based on hepcidin trends in this population should be pursued.
- 3 November 2023
- Published by S. Karger AG in Blood Purification
- Vol. 53  (1) , 23-29
Hepcidin Removal during Continuous Renal Replacement Therapy
Introduction: Patients with acute kidney injury (AKI) or end stage kidney disease (ESKD) may require continuous renal replacement therapy (CRRT) as a supportive intervention. While CRRT is effective at achieving solute control and fluid balance, the indiscriminate nature of this procedure raises the possibility that beneficial substances may similarly be removed. Hepcidin, an antimicrobial peptide with pivotal roles in iron homeostasis and pathogen clearance, has biochemical properties amenable to direct removal via CRRT. We hypothesized that serum hepcidin levels would significantly decrease after initiation of CRRT. Methods: In this prospective, observational trial, we enrolled 13 patients who required CRRT: 11 due to stage 3 AKI, and 2 due to critical illness in the setting of ESKD. Plasma was collected at the time of enrollment, and then plasma and effluent were collected at 10:00 a.m. on the following 3 days. Plasma samples were also collected from healthy controls, and we compared hepcidin concentrations in those with renal disease compared to normal controls, evaluated trends in hepcidin levels over time, and calculated the hepcidin sieving coefficient. Results: Plasma hepcidin levels were significantly higher in patients initiating CRRT than in normal controls (158 ± 60 vs. 17 ± 3 ng/mL respectively, p < 0.001). Hepcidin levels were highest prior to CRRT initiation (158 ± 60 ng/mL), and were significantly lower on day 1 (102 ± 24 ng/mL, p < 0.001) and day 2 (56 ± 14 ng/mL, p < 0.001) before leveling out on day 3 (51 ± 11 ng/mL). The median sieving coefficient was consistent at 0.82–0.83 for each of 3 days. Conclusions: CRRT initiation is associated with significant decreases in plasma hepcidin levels over the first 2 days of treatment regardless of indication for CRRT, or presence of underlying ESKD. Since reduced hepcidin levels are associated with increased mortality and our data implicate CRRT in hepcidin removal, larger clinical studies evaluating relevant clinical outcomes based on hepcidin trends in this population should be pursued.
- 1 September 2023
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 325  (3) , F328-F344
IL-6 mediates the hepatic acute phase response after prerenal azotemia in a clinically defined murine model
Prerenal azotemia (PRA) accounts for a third of acute kidney injury (AKI) cases yet is rarely studied in preclinical models. We developed a clinically defined murine model of prerenal azotemia characterized by a 75% decrease in measured glomerular filtration rate (GFR), return of measured glomerular filtration rate to baseline with resuscitation, and absent tubular injury. Numerous systemic effects were observed, such as increased plasma interleukin-6 (IL-6) and upregulation of the hepatic acute phase response.
- 1 September 2023
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 325  (3) , F328-F344
IL-6 mediates the hepatic acute phase response after prerenal azotemia in a clinically defined murine model
Prerenal azotemia (PRA) accounts for a third of acute kidney injury (AKI) cases yet is rarely studied in preclinical models. We developed a clinically defined murine model of prerenal azotemia characterized by a 75% decrease in measured glomerular filtration rate (GFR), return of measured glomerular filtration rate to baseline with resuscitation, and absent tubular injury. Numerous systemic effects were observed, such as increased plasma interleukin-6 (IL-6) and upregulation of the hepatic acute phase response.